Pictet Asset Management Holding SA Has $128.66 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Pictet Asset Management Holding SA reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,540,485 shares of the biopharmaceutical company’s stock after selling 78,783 shares during the period. Pictet Asset Management Holding SA owned approximately 1.45% of Intra-Cellular Therapies worth $128,661,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ITCI. Cerity Partners LLC lifted its position in shares of Intra-Cellular Therapies by 62.9% during the 3rd quarter. Cerity Partners LLC now owns 44,107 shares of the biopharmaceutical company’s stock worth $3,227,000 after buying an additional 17,027 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Intra-Cellular Therapies by 1.3% during the third quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company’s stock worth $1,614,000 after acquiring an additional 283 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Intra-Cellular Therapies by 13.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company’s stock worth $1,648,000 after acquiring an additional 2,622 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Intra-Cellular Therapies by 3.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company’s stock valued at $23,649,000 after purchasing an additional 11,104 shares in the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $2,195,000. 92.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ITCI has been the topic of a number of research analyst reports. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Friday. They issued a “hold” rating on the stock. Piper Sandler reissued a “neutral” rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Royal Bank of Canada reissued a “sector perform” rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Ten research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Up 0.0 %

Shares of ITCI stock opened at $131.81 on Friday. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.87. The firm has a 50 day moving average of $129.12 and a 200-day moving average of $99.45. The company has a market cap of $14.04 billion, a price-to-earnings ratio of -151.50 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.